AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22901697 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline in systolic BP starting at older ages
Number of subjects: 63
Study 22901697 — intervention group
Group type: COMPARATOR
Intervention: Body mass index, cholesterol, or apolipoprotein E ε4 allele
Number of subjects: 63
Study 22068930 — intervention group
Group type: EXPERIMENTAL
Intervention: sports-cADHD (90-min athletic activity, twice a week for 6 weeks)
Number of subjects: 28
Study 22068930 — intervention group
Group type: COMPARATOR
Intervention: edu-cADHD (education on behavior control)
Number of subjects: 28
Study 18551282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone
Number of subjects: 28
Study 18551282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16490806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 0
Study 16490806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 0
Study 16490806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (both doses)
Number of subjects: 0
Study 12390425 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cystatin C
Number of subjects: 19
Study 12390425 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 19
Study 12390425 — intervention group
Group type: COMPARATOR
Intervention: Serum cystatin C and serum creatinine
Number of subjects: 19
Study 10429599 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorientation measures during the perioperative phase (including presurgery admission to the orthopedic ward, home visits, access to reorientation devices such as a large clock, calendar, radio, TV-set, telephone, and encouragement to wear own clothing)
Number of subjects: 223
Study 10429599 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without reorientation measures)
Number of subjects: 223
Study 10429599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (reorientation measures vs control)
Number of subjects: 223
Study 7739278 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein serum levels in primary thrombocytosis group (27 patients)
Number of subjects: 89
Study 7739278 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein serum levels in secondary thrombocytosis group (62 patients)
Number of subjects: 89
Study 7739278 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (54 patients)
Number of subjects: 89
Study 7739278 — intervention group
Group type: COMPARATOR
Intervention: Comparison of C-reactive protein levels between groups
Number of subjects: 89
Study 1697283 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 40
Study 1697283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HAES-steril)
Number of subjects: 40
Study 6457152 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of the alpha-blocker thymoxamine given by inhalation
Number of subjects: 10
Study 6457152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31577692 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 608
Study 30087199 — intervention group
Group type: EXPERIMENTAL
Intervention: T/A group (adenotonsillectomy)
Number of subjects: 140
Study 30087199 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual waiting period for surgery)
Number of subjects: 140
Study 27591461 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block with single needle prick in T4 with 0.5% ropivacaine+adrenaline 3μgmL(‐1) with a volume of 0.3mLkg(‐1) preoperatively
Number of subjects: 80
Study 27591461 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 80
Study 25410412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual assault resistance education program
Number of subjects: 899
Study 22677643 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%
Number of subjects: 60
Study 22677643 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate without pranoprofen
Number of subjects: 60
Study 20461969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 33
Study 20461969 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (MK) 10 mg/d
Number of subjects: 33
Study 18657569 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based drug abuse prevention program (12-hour class-based curriculum)
Number of subjects: 7079
Study 15709845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 227
Study 15709845 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 227
Study 15709845 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with clinical management
Number of subjects: 227
Study 11792333 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 212
Study 11792333 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 212
Study 10069784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors (smoking, serum total cholesterol, HDL cholesterol, blood pressure, body mass index, diabetes)
Number of subjects: 14786
Study 10069784 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related increase in risk factor levels
Number of subjects: 14786
Study 10069784 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in HDL cholesterol and smoking
Number of subjects: 14786
Study 7547089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg day-1)
Number of subjects: 18
Study 7547089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7547089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium (single dose)
Number of subjects: 18
Study 7547089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 18
Study 7547089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 18
Study 2326032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine with diazepam, meperidine, and nitrous oxide
Number of subjects: 40
Study 2326032 — intervention group
Group type: COMPARATOR
Intervention: Methohexital sodium
Number of subjects: 40
Study 7284544 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (not specified)
Number of subjects: 0
Study 7284544 — intervention group
Group type: COMPARATOR
Intervention: Control population
Number of subjects: 0
Study 30985704 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT
Number of subjects: 18
Study 30985704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27909031 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel from flax seed oil
Number of subjects: 49
Study 27909031 — intervention group
Group type: COMPARATOR
Intervention: Hand splint
Number of subjects: 49
Study 26691413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 12
Study 26691413 — intervention group
Group type: COMPARATOR
Intervention: Sprint Interval Training (SIT)
Number of subjects: 12
Study 26691413 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HIIT and SIT
Number of subjects: 12
Study 24467781 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐week group Cognitive Behavioural Therapy (CBT) treatment
Number of subjects: 18
Study 24467781 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (8‐week clinical monitoring preceding treatment)
Number of subjects: 18
Study 22198452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) 12.5-75 mg/d, titrated according to a fixed, flexible schedule
Number of subjects: 41
Study 22198452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20633266 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsimax (2 mg capsaicinoids in a microencapsulated matrix)
Number of subjects: 20
Study 20633266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17414459 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, and 5‐fluorouracil)
Number of subjects: 343
Study 17414459 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF/thiotepa, Adriamycin, vinblastine, and Halotestin (TsAVbH)
Number of subjects: 343
Study 17414459 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval > or = 2 years
Number of subjects: 343
Study 17414459 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of disease-free interval < 2 years
Number of subjects: 343
Study 16382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 34
Study 16382379 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 34
Study 12118626 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement program (group-based)
Number of subjects: 167
Study 12118626 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 167
Study 10447523 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microaneurysms
Number of subjects: 2424
Study 10447523 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of microaneurysms
Number of subjects: 2424
Study 1293732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (single dose)
Number of subjects: 700
Study 1293732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (multiple doses)
Number of subjects: 700
Study 6703638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 108
Study 6703638 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 108
Study 30699151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B 1mg/kg for 2 weeks and oral Fluconazole 800mg daily for 10 weeks
Number of subjects: 112
Study 30699151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever being re‐admitted since discharge after hospital‐based management of CCM
Number of subjects: 112
Study 30699151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived quality of life 50-75%
Number of subjects: 112
Study 30699151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived quality of life >75%
Number of subjects: 112
Study 29288137 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial (RCT) group
Number of subjects: 82430
Study 29288137 — intervention group
Group type: EXPERIMENTAL
Intervention: Men choosing treatment
Number of subjects: 82430
Study 29288137 — intervention group
Group type: COMPARATOR
Intervention: Excluded men with advanced cancer/comorbidities
Number of subjects: 82430
Study 27382816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 80
Study 27382816 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study 25801892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen (IR) of cholecalciferol (300.000 UI at baseline and 50.000 UI/monthly)
Number of subjects: 34
Study 25801892 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (SR) of cholecalciferol (25.000 UI monthly)
Number of subjects: 34
Study 25801892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (IR and SR)
Number of subjects: 34
Study 23719555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 supplementation (n = 40)
Number of subjects: 857
Study 23719555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 49)
Number of subjects: 857
Study 23719555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum vitamin K1
Number of subjects: 857
Study 23719555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum vitamin K1 in antihypertension medication users
Number of subjects: 857
Study 19932057 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 21
Study 19932057 — intervention group
Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 21
Study 17982167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 40
Study 17982167 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil (SR)
Number of subjects: 40
Study 16600506 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.14 mg/kg)
Number of subjects: 20
Study 16600506 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl, 0.9%)
Number of subjects: 20
Study 14551369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled dialysers
Number of subjects: 23
Study 14551369 — intervention group
Group type: COMPARATOR
Intervention: Dry dialysers
Number of subjects: 23
Study 10808170 — intervention group
Group type: EXPERIMENTAL
Intervention: MF DPI 50 microg twice daily
Number of subjects: 15
Study 10808170 — intervention group
Group type: EXPERIMENTAL
Intervention: MF DPI 100 microg twice daily
Number of subjects: 15
Study 10808170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9228350 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol for 6 weeks, increased in stepwise fashion at 2-week intervals
Number of subjects: 19
Study 9228350 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo for 6 weeks
Number of subjects: 19
Study 8497871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg/day) with reduced cyclosporine doses
Number of subjects: 43
Study 8497871 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of cyclosporine
Number of subjects: 43
Study 8497871 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of cyclosporine with ketoconazole
Number of subjects: 43
Study 3027838 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole twice a day for five days
Number of subjects: 47
Study 3027838 — intervention group
Group type: COMPARATOR
Intervention: 100 mg itraconazole once a day for five days
Number of subjects: 47
Study 3027838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 47
Study 28877139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 66
Study 28877139 — intervention group
Group type: COMPARATOR
Intervention: Supportive Care (SC)
Number of subjects: 66
Study 28369443 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention
Number of subjects: 0
Study 28369443 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23907764 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal insulin
Number of subjects: 48
Study 23907764 — intervention group
Group type: COMPARATOR
Intervention: 30 mg oral cortisol
Number of subjects: 48
Study 23907764 — intervention group
Group type: COMPARATOR
Intervention: Both insulin and cortisol
Number of subjects: 48
Study 23907764 — intervention group
Group type: COMPARATOR
Intervention: Neither (placebo)
Number of subjects: 48
Study 22272611 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 5-mg daily for 4 weeks
Number of subjects: 144
Study 22272611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 20369760 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M: 2 ml of 0.5% hyperbaric bupivacaine plus morphine 100 microg plus fentanyl 15 microg, mixed in a syringe
Number of subjects: 48
Study 20369760 — intervention group
Group type: COMPARATOR
Intervention: Group S: 2 ml of 0.5% bupivacaine followed by morphine 100 microg plus fentanyl 15 microg through a separate syringe
Number of subjects: 48
Study 18662943 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to a combination of emtricitabine, didanosine and efavirenz for 48 weeks
Number of subjects: 158
Study 18662943 — intervention group
Group type: COMPARATOR
Intervention: Continue zidovudine regimen
Number of subjects: 158
Study 18662943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 15728401 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (n = 26, 1-2 mg/day temocapril or trandolapril)
Number of subjects: 49
Study 15728401 — intervention group
Group type: COMPARATOR
Intervention: Calcium-channel blockers (CCB, n = 23, 2.5-5 mg/day amlodipine)
Number of subjects: 49
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 25 micro g/d
Number of subjects: 67
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 125 micro g/d
Number of subjects: 67
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 250 micro g/d
Number of subjects: 67
Study 12499343 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 0 micro g/d (control)
Number of subjects: 67
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Total input from all sources (supplement, food, tissue stores)
Number of subjects: 67
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue stores
Number of subjects: 67
Study 12499343 — intervention group
Group type: EXPERIMENTAL
Intervention: Current recommended vitamin D inputs
Number of subjects: 67
Study 10584680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of type A and type F botulinum toxins (5 units each)
Number of subjects: 54
Study 10584680 — intervention group
Group type: COMPARATOR
Intervention: Type A botulinum toxin alone
Number of subjects: 54
Study 10584680 — intervention group
Group type: COMPARATOR
Intervention: Type F botulinum toxin alone
Number of subjects: 54
Study 8838194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg five times daily)
Number of subjects: 691
Study 8838194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 1497518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injections of fluorouracil (4 to 6 injections for 10 days after surgery)
Number of subjects: 50
Study 1497518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluorouracil injections)
Number of subjects: 50
Study 1497518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injections of fluorouracil
Number of subjects: 50
Study 6614128 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 4
Study 6614128 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific play intervention
Number of subjects: 4
Study 30303695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 100 mg per day for 8 weeks
Number of subjects: 60
Study 30303695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose acetate 100 mg per day for 8 weeks)
Number of subjects: 60
Study 29741661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B testing offered by CHCs
Number of subjects: 3733
Study 29741661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C testing offered by CHCs
Number of subjects: 3733
Study 29741661 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of benefits for providing hepatitis testing
Number of subjects: 3733
Study 29741661 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for not offering hepatitis testing
Number of subjects: 3733
Study 29741661 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants for offering hepatitis B and C testing
Number of subjects: 3733
Study 27892422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐6MWT
Number of subjects: 155
Study 24266780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 47
Study 24266780 — intervention group
Group type: COMPARATOR
Intervention: No cardiopulmonary bypass (No CPB)
Number of subjects: 47
Study 22951801 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy program for treatment of co-dependence
Number of subjects: 142
Study 19383224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative oral administration of magnesium for 10 days
Number of subjects: 0
Study 19383224 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative flush infusion of magnesium
Number of subjects: 0
Study 17449998 — intervention group
Group type: EXPERIMENTAL
Intervention: PMG incorporating systematic graded exposure
Number of subjects: 143
Study 17449998 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual PMG treatment
Number of subjects: 143
Study 17449998 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 143
Study 15223903 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin doses (four doses compared)
Number of subjects: 85
Study 15223903 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related complications (graft-versus-host disease and repeated infections)
Number of subjects: 85
Study 15223903 — intervention group
Group type: COMPARATOR
Intervention: Baseline status
Number of subjects: 85
Study 12095662 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance contingency (N=55)
Number of subjects: 110
Study 12095662 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent incentives (N=55)
Number of subjects: 110
Study 12095662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance after the study
Number of subjects: 110
Study 12095662 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance contingency group
Number of subjects: 110
Study 9619936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory chemotherapy
Number of subjects: 500
Study 9619936 — intervention group
Group type: COMPARATOR
Intervention: Bed rest in hospital
Number of subjects: 500
Study 9619936 — intervention group
Group type: COMPARATOR
Intervention: Plaster-of-Paris jacket
Number of subjects: 500
Study 9619936 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid for 18 months
Number of subjects: 500
Study 9619936 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid plus streptomycin for the first three months
Number of subjects: 500
Study 9619936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical excision of the spinal lesion with bone graft
Number of subjects: 500
Study 9619936 — intervention group
Group type: COMPARATOR
Intervention: Open debridement
Number of subjects: 500
Study 9619936 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course regimes based on isoniazid and rifampicin
Number of subjects: 500
Study 7698688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty test meal
Number of subjects: 7